Latest news with #bloodglucose
Medical News Today
2 days ago
- Health
- Medical News Today
2 low-calorie days a week could aid weight loss, blood sugar control in diabetes
Weight loss can be effective in managing type 2 diabetes, a condition where a person cannot control their blood glucose losing weight can be challenging, so finding a method of weight control that fits with a person's lifestyle is important.A new study has shown that several forms of energy restriction can help people with obesity and type 2 diabetes to lose weight and manage their blood the 5:2 diet, time-restricted eating, and continuous energy restriction were all beneficial, experts suggest that people opt for the form of energy restriction they find easiest to 2 diabetes is an increasingly common condition, and a serious public health concern. Forecasts predict that it will affect close to 10% of the world's population by condition, in which a person's cells stop responding to insulin, resulting in uncontrolled blood glucose (sugar) levels, is strongly linked to overweight and obesity. Losing weight can help to manage the symptoms, and significant weight loss may even reverse type 2 diabetes in some people.A new study from The First Affiliated Hospital of Zhengzhou University, China, tested three methods of energy restriction for weight loss and blood glucose control in people with obesity and type 2 diabetes. The study, which was presented at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, CA, suggests that while all three methods showed benefits, intermittent energy restriction (IER) — characterized by 5 days normal eating and 2 days of very low energy intake each week — was slightly more effective in reducing fasting blood glucose, improving insulin sensitivity, and lowering findings are yet to appear in a peer-reviewed researcher Haohao Zhang, PhD, chief physician at The First Affiliated Hospital of Zhengzhou University in Zhengzhou, China, told Medical News Today:'All three dietary approaches — IER, TRE [time-restricted eating], and CER [continuous energy restriction] — were beneficial because they reduced total calorie intake, a key factor in improving glycemic control (HbA1c) and promoting weight loss in obese individuals with type 2 diabetes. Regardless of the method, calorie restriction facilitated weight loss, reducing insulin resistance and improving glycemic control.'3 ways to reduce energy intake in diabetesThe researchers recruited 90 people with type 2 diabetes and obesity into their study. They then randomly assigned them to three groups, each of which followed a different diet program. At the start, participants had a mean age of 36.8 years, and a mean duration of type 2 diabetes of 1.5 total, 63 people (18 women and 45 men) completed the 16-week, nutritionist-supervised researchers measured glycated haemoglobin (HbA1c) — a standard test for type 2 diabetes that measures blood glucose over the previous 90 days — at the start and end of the trial. Optimal HbA1c is less than 5.7%, with 6.5% or over indicating type 2 the start of the study participants had a mean HbA1c, of 7.42%, and a mean body mass index (BMI) of 31.7 kilograms per square meter (kg/m²).Each group followed one of three low-calorie diet programs, with the same overall energy intake each week, as Zhang explained to MNT:intermittent energy restriction (IER) — This group consumed very low calories (500–600 kilocalories [kcal]) on two nonconsecutive days per week, with normal eating on the remaining 5 days, adhering to a weekly total calorie goal. Eating times were not restricted, but calorie intake was limited on fasting eating (TRE) — Participants ate within a 10-hour window (6–8 am to 4–6 pm) each day, fasting for the remaining 14 hours. Within the eating window, food intake was controlled to match the weekly calorie goal consistent across all energy restriction (CER) — These people followed a low-calorie diet without specific time restrictions, maintaining a consistent weekly calorie deficit to match the other groups' weekly calorie intake. Which diet leads to weight loss and better blood glucose control?Participants in all three groups lost weight and showed better blood glucose control by the end of the 16-week study. Mean weight loss for the 3 groups was 7.5 kilograms (kg), with those in the IER group losing the most, and participants in all three groups reduced their HbA1c by more than 1%.David M. Cutler, MD, a board-certified family medicine physician at Providence Saint John's Health Center in Santa Monica, CA, not involved in the study, told MNT that:'Data from the study showed statistically significant benefit in weight loss and reduction in hemoglobin A1c, which indicates better control of diabetes. However, there was no statistically significant difference between the three groups for these measures.'Further research needed in diverse populationsCutler pointed out that: 'This study was conducted at The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China. So, it remains to be seen if such dietary restrictions would yield similar results in an American population. Further research would need to be done in a larger, more diverse population to see which form of dietary restriction is most likely to be beneficial.'Zhang agreed, saying that future studies should 'include broader populations — e.g. [of] varying ages, ethnicities, or diabetes durations — to assess the generalizability of these dietary approaches, and explore psychological and behavioral factors affecting adherence to IER, TRE, and CER to optimize patient support and intervention design.'What is the best way to lose weight and manage type 2 diabetes?'The fact that only 63 of the 90 patients actually completed the study speaks to the fact that adhering to dietary restrictions is difficult,' Cutler told recommended the 5:2 diet 'due to its greater benefits in reducing fasting blood glucose, improving insulin sensitivity, lowering triglycerides, and achieving higher compliance (85%).'He added that it 'offers flexibility, allowing normal eating for five days and calorie restriction on two non-consecutive days, which may be easier to sustain than daily restrictions (CER) or strict eating windows (TRE).''However,' he told MNT that people should consult a dietitian and that, 'the choice should be individualized, considering patient preferences, lifestyle, and adherence capacity.'Both he and Cutler emphasized that any weight-loss regime will benefit people with obesity and type 2 diabetes, with Cutler concluding that:'The major take home message seems to be that any dietary restriction can be helpful for weight loss and managing type 2 diabetes if [the] patient will stick to it. My personal recommendation is to eat less, and mostly vegetables. And for people who want more structure than that, they should try any form of intermittent fasting or specific calorie restriction which is most appealing to them.'
Medscape
20-06-2025
- Health
- Medscape
Brief Use of CGM May Enhance Lifestyle Awareness in T2D
TOPLINE: Short-term use of continuous glucose monitoring (CGM) provided valuable insights into lifestyle factors affecting blood glucose levels in people with type 2 diabetes (T2D) who were not on insulin therapy, particularly in those with a diabetes duration of less than 5 years. METHODOLOGY: CGM is an effective strategy for managing blood glucose levels in people with non-insulin-treated T2D; this study focused on the insights gained regarding lifestyle factors affecting blood glucose levels over a 2-week period of usage. Participants with non-insulin-treated T2D across 20 cities in Denmark received a single CGM device during a walk-in setup, with minimal guidance provided during device installation. They used the CGM device for a maximum of 14 days. Baseline questionnaires were completed onsite, with follow-up surveys sent via email after 2 weeks and after 3 months. TAKEAWAY: A total of 724 participants completed the second questionnaire sent after 2 weeks. Of these, 80% found CGM highly useful and informative for managing T2D. Participants with a diabetes duration of less than 5 years engaged in more daily scans (80% vs 71%) and reported greater insights into the effects of lifestyle on glucose levels — including food (88% vs 78%), portion sizes (80% vs 60%), and physical activity (65% vs 55%) — than those with a diabetes duration of more than 5 years. Education level did not significantly affect the knowledge gained from CGM usage. At the 3-month follow-up, 50% of participants reported maintaining behavioral changes based on their CGM experience. IN PRACTICE: "These insights may encourage long-term behavioral changes, potentially leading to improved glycemic control," the authors wrote. SOURCE: The study was led by Emma Munch Nielsen, Glostrup, Denmark. It was presented by Tanja Thybo, Glostrup, Denmark, on June 20, 2025, at the 85th Scientific Sessions - American Diabetes Association, held at the McCormick Place Convention Center, Chicago. LIMITATIONS: No limitations were discussed in the abstract. DISCLOSURES: No funding details were disclosed. Three authors disclosed relationships with Abbott. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Daily Mail
17-06-2025
- Health
- Daily Mail
BREAKING NEWS Recall for medical device used by 38m Americans over malfunction that could lead to death
An urgent recall has gone out for a popular medical devices used by millions of Americans with diabetes. The US Food and Drug Administration (FDA) has revealed that over two million blood glucose monitors from Dexcom could fail to give the audible warning that the wearer is dealing with high or low blood sugar levels. This could lead to users to miss critical warnings, increasing the risk of serious health problems like seizures, vomiting, fainting, or even death from untreated hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar). The recall effects the Dexcom G6 Glucose Receiver, Dexcom G7 Glucose Receiver, Dexcom One+ Continuous Glucose Monitoring System, and the Dexcom One Continuous Glucose Monitoring Syste. In total, 2,230,770 Dexcom devices are a part of the recall. The FDA has just designated the recall as a 'Class I' alert, their most severe grade, which means the problem could cause serious harm or death. The problem in all four devices revolves around defective foam or an assembly error that can cause the speaker in the devices to lose contact with the internal circuit board. This can cause the wearable monitor to stop sounding an alarm when the user's blood sugar enters dangerous zones. Over 38 million Americans have diabetes. Nearly 100 million American adults have prediabetes, according to data and estimates from the CDC. This is a developing story. More updates to follow.
Associated Press
28-05-2025
- Business
- Associated Press
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
RUTHERFORD, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Victoria E. Carr-Brendel, PhD, was elected to the Company's Board of Directors, effective May 22, 2025. 'We are delighted to welcome Dr. Carr-Brendel to Glucotrack's Board of Directors,' said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. 'With her exceptional leadership in medical devices and deep expertise in implantable technologies, she will be an invaluable addition to the Board as we advance our continuous blood glucose monitoring (CBGM) technology through clinical development and move closer to commercialization.' Dr. Carr-Brendel currently serves as a member of the board of directors of Vicarious Surgical Inc. (NYSE: RBOT) since January 2023 and previously served from 2018 to 2024 as President and Group Vice President of Cochlear Implants at Sonova Group. Prior to that, she served as Chief Executive Officer of JenaValve Technology, Inc., a medical device company focused on developing minimally invasive transcatheter aortic valve repair systems for patients suffering from severe aortic valve disease. Previously, Dr. Carr-Brendel held various leadership roles at Boston Scientific, including overseeing the acquisition of Bayer's interventional radiology division in 2014. She started her career as a scientist in R&D with roles at Dexcom and Baxter Healthcare, amassing over forty patents and taking on increasingly senior business and management roles. She holds a BA in Biology from Monmouth College, an MS in Microbiology from Iowa State University, and a PhD in Microbiology and Immunology from the University of Illinois at Chicago. 'I am honored to be joining Glucotrack's Board of Directors at this pivotal time in the company's development,' said Victoria E. Carr-Brendel, PhD. 'The innovative CBGM has tremendous potential to address significant unmet needs for people with diabetes and enhance automated insulin delivery. I look forward to contributing to the Company as it works to achieve its strategic and clinical milestones.' Glucotrack's CBGM is a long-term implantable system with no wearable component, designed for up to three years of continuous, accurate blood glucose monitoring, offering a more convenient and less intrusive glucose monitoring solution. The CBGM measures glucose directly from blood, unlike traditional continuous glucose monitoring systems which measure glucose from interstitial fluid. Thus, it aims to provide real-time readings without the lag time typically associated with interstitial glucose measurements. The Glucotrack Continuous Blood Glucose Monitor is an Investigational Device and is limited by federal (or United States) law to investigational use. For more information about Glucotrack's CBGM technology, visit Information on the Company's website does not constitute a part of and is not incorporated by reference into this press release. About Glucotrack, Inc. Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes. Glucotrack's CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as 'anticipate', 'believe', 'expect', 'plan' and 'will' are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack's results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack's future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack's filings with the U.S. Securities and Exchange Commission (the 'SEC'), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025. Contacts: Investor Relations: [email protected] Media: [email protected]
Bloomberg
17-05-2025
- Health
- Bloomberg
MAHA Is Pushing Glucose Tracking That Most People Don't Need
Casey Means, a Stanford-trained physician and wellness influencer nominated by President Donald Trump for surgeon general, is convinced the US is experiencing an epidemic of metabolic dysfunction — a crisis silently unfolding inside the cells of millions of Americans. One solution, she says, is giving people a close-up view of that crisis. Coincidentally, Levels, a company she co-founded, sells a system that allows people to continuously track their blood glucose levels in real time. She claims this information can help people home in on food and lifestyle choices that will improve their metabolic health.
